Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Pim W. M. van Dorst"'
Autor:
Richard M. Tjon Joe Gin, Emanuele Barbato, Thomas O. Bergmeijer, Arnoud W J van 't Hof, Pim W. M. van Dorst, Daniel M.F. Claassens, Arend Mosterd, Vera H.M. Deneer, Renicus S Hermanides, Carmine Morisco, Folkert W. Asselbergs, Willem Dewilde, Gerrit J.A. Vos, C. Boersma, Pim van der Harst, Jean-Paul R. Herrman, Jurriën M. ten Berg, Maarten J. Postma
Publikováno v:
American Journal of Cardiovascular Drugs, 22(2), 195-206. Adis International Ltd
American journal of cardiovascular drugs, 22(2), 195-206. ADIS INT LTD
American journal of cardiovascular drugs, 22(2), 195-206. ADIS INT LTD
INTRODUCTION: The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2Y12 inhibitor strategy reduced bleeding rates compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524e9c700d35d5b49880db1ea1289396
http://hdl.handle.net/11588/857926
http://hdl.handle.net/11588/857926
Autor:
Daniel M F, Claassens, Pim W M, van Dorst, Gerrit J A, Vos, Thomas O, Bergmeijer, Renicus S, Hermanides, Arnoud W J, van 't Hof, Pim, van der Harst, Emanuele, Barbato, Carmine, Morisco, Richard M, Tjon Joe Gin, Folkert W, Asselbergs, Arend, Mosterd, Jean-Paul R, Herrman, Willem J M, Dewilde, Maarten J, Postma, Vera H M, Deneer, Jurriën M, Ten Berg, Cornelis, Boersma
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 22(2)
The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2YIn this analysis, we aimed to evaluate the cost effectiveness of a genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel.A 1-year decision tree
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2efc2d844eddc5888d596f5b53a046e3
https://pubmed.ncbi.nlm.nih.gov/34490590
https://pubmed.ncbi.nlm.nih.gov/34490590
